IN8BIO, INC. Logo

IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for cancer.

INAB | US

Overview

Corporate Details

ISIN(s):
US45674E1091
LEI:
Country:
United States of America
Address:
EMPIRE STATE BUILDING, 10118 NEW YORK

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform utilizes allogeneic, autologous, and genetically modified approaches to develop novel cell therapies. IN8BIO was the first to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400, a Phase 2 asset for newly diagnosed glioblastoma (GBM), and INB-100, a Phase 1 candidate for patients with leukemia undergoing hematopoietic stem cell transplantation. The company is also advancing a broad portfolio of preclinical programs focused on solid tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Cyfuse Biomedical K.K. Logo
Develops scaffold-free bio 3D printing technology for tissue and organ fabrication.
Japan
4892
CYTOKINETICS INC Logo
A late-stage biopharma developing drugs for diseases of impaired muscle function.
United States of America
CYTK
CytomX Therapeutics, Inc. Logo
Clinical-stage oncology company developing conditionally activated biologics.
United States of America
CTMX
Cytori Cell Research Institute,Inc. Logo
Develops cell therapy medical devices using a patient's own adipose tissue.
Japan
3750
Daebonglsco.,Ltd Logo
Develops and supplies raw materials for the pharmaceutical, cosmetic, and food industries.
South Korea
078140
DaehanPharmaceutical Logo
Researches, develops, and manufactures human/animal pharma and bio-pharmaceuticals.
South Korea
023910
DAE HWA PHARM CO., LTD Logo
Pharmaceutical firm developing drugs with proprietary drug delivery system technologies.
South Korea
067080
Daesung Microbiological Labs. Co. Ltd Logo
Develops, manufactures, and distributes animal pharmaceuticals and vaccines.
South Korea
036480
DAEWON PHARMACEUTICAL CO.,LTD Logo
Develops and manufactures prescription drugs and finished pharmaceutical products.
South Korea
003220
DAEWOONG CO.,LTD Logo
A holding company in the biotech and healthcare sectors developing pharmaceuticals.
South Korea
003090

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.